github link
Accession IconGSE74761

Extensive alopecia areata is reversed by IL-23 cytokine antagonism

Organism Icon Homo sapiens
Sample Icon 9 Downloadable Samples
Technology Badge Icon Affymetrix Human Genome U133 Plus 2.0 Array (hgu133plus2)

Submitter Supplied Information

Description
Alopecia areata (AA) is a prevalent disease associated with major emotional distress, and lacks effective, safe therapeutics for patients with extensive hair loss. This is the first report of hair regrowth with specific cytokine antagonism, in three patients with extensive hair loss ranging from 40% scalp involvement to alopecia universalis. Ustekinumab, an IL-12/23p40 antagonist that is highly effective in psoriasis, showed impressive ability to induce hair regrowth, coupled with suppression of inflammatory pathways and upregulation of hair keratins. Our report suggests that extensive AA is reversible using targeted treatments, opening the door for specific cytokine antagonism for this debilitating disease.
PubMed ID
Total Samples
11
Submitter’s Institution

Samples

Show of 11 Total Samples
Filter
Add/Remove
Accession Code
Title
Sex
Specimen part
Disease stage
Subject
Time
Processing Information
Additional Metadata
3_NL_Week_0
female
non-lesional
alopecia areata (aa) patient
3
pre-treatment; baseline
5_Normal_Week_0
na
normal
healthy individual
5
pre-treatment; baseline
1_LS_Week_20
male
lesional
alopecia areata (aa) patient
1
post-treatment with 90 mg ustekinumab treatment
4_NL_Week_0
male
non-lesional
alopecia areata (aa) patient
4
pre-treatment; baseline
3_LS_Week_0
female
lesional
alopecia areata (aa) patient
3
pre-treatment; baseline
1_LS_Week_0
male
lesional
alopecia areata (aa) patient
1
pre-treatment; baseline
4_LS_Week_0
male
lesional
alopecia areata (aa) patient
4
pre-treatment; baseline
4_LS_Week_20
male
lesional
alopecia areata (aa) patient
4
post-treatment with 90 mg ustekinumab treatment
7_Normal_Week_0
na
normal
healthy individual
7
pre-treatment; baseline
Sample not processed
Learn more
3_LS_Week_20
female
lesional
alopecia areata (aa) patient
3
post-treatment with 90 mg ustekinumab treatment
NA
Loading...